Jagsonpal Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on April 27, 2026, recommended Final Dividend of Rs. 4 per equity share.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals reported audited standalone financial results for FY 2025-26 ended March 31, 2026. Total income stood at Rs. 2,992.20 million, up 8% from Rs. 2,769.06 million in the previous year. Net profit remained relatively flat at Rs. 553.61 million compared to Rs. 555.80 million. The Board recommended a final dividend of Rs. 4 per equity share (200% on face value of Rs. 2) for FY 2025-26, subject to shareholder approval. Additionally, the Board approved a buy-back of up to 1.6 million equity shares at Rs. 250 per share, aggregating not more than Rs. 400 million through the tender offer route. Reserves as of March 2026 stood at Rs. 2,627.79 million.
The dividend recommendation and buy-back announcement are positive signals for shareholders. The buy-back at Rs. 250 per share offers significant value, and the company maintains strong reserves. However, profit before tax declined to Rs. 575.18 million from Rs. 698.59 million due to exceptional items including Rs. 20.79 million in employee benefit expenses from new labour codes.